Liver cirrhosis, Hepatocellular carcinoma LC HCC
Conditions
Interventions
Ingested ingredients: MCT oil
Dosage: Start with 6g at a time and take 30-36g / day (10-12g / meal) daily.
Intake period: 3 months
Nutritional guidance and intake situation, the confirmation of the sy
Sponsors
Sakaki Masashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with liver cirrhosis or hepatocellular carcinoma who are visiting the Department of Gastroenterology, Showa University Hospital. 2) Patients with albumin 4.0 mg / dL or less. 3) Patients who are 20 years of age or older at the time of obtaining consent. 4) Patients who have given written consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Patients with uncontrolled hepatic encephalopathy. 2) Patients who require ascites puncture (twice or more a month). 3) Decompensated cirrhosis in patients with T-Bil of 3 or higher or in Child-Pugh classification grade C. 4) Patients who are judged to be ineligible by the judgment of the research doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of albumin level, prealbumin level, and retinol-binding protein by MCT diet | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of liver function (Child-Pugh score, ALBI-grade) Evaluation of amino acid balance (Fischer ratio) Evaluation of lipid composition Evaluation of muscle mass Evaluation of body composition | — |
Contacts
Public ContactMasashi Sakaki
Showa University
Outcome results
None listed